hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06314802 id: LCSR briefTitle: Learning Curve of the Shouldice Procedure acronym: LCSR overallStatus: RECRUITING date: 2024-03-11 date: 2024-05-11 date: 2024-06-10 date: 2024-03-18 date: 2024-03-18 name: Shouldice Hospital class: OTHER briefSummary: Hernia repair surgery is common, especially the Shouldice repair for primary inguinal hernias, which is considered a top-notch nonmesh technique. However, outcomes can vary, possibly due to differences in surgical skill and experience. Many surgeons are trained more in mesh repairs like the Lichtenstein technique, rather than nonmesh repairs like Shouldice.
This research aims to give surgeons and the hernia community valuable insights into improving surgical techniques and patient outcomes. conditions: Groin Hernia conditions: Shouldice Procedure studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 1600 type: ESTIMATED name: no intervention measure: Operating time I measure: Operating time II measure: Operating time III sex: ALL minimumAge: 16 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Shouldice hospital status: RECRUITING city: Thornhill state: Ontario zip: L3T 4A3 country: Canada name: Christoph Paasch role: CONTACT phone: 9058891125 email: cpaasch@shouldice.com name: Marguerite Mainprize role: CONTACT phone: 9058891125 email: mmainprize@shouldice.com hasResults: False
nctId: NCT06314789 id: G1201 briefTitle: The Use of Lung Ultrasonography in the Delivery Room in Neonates acronym: LUSIN overallStatus: ENROLLING_BY_INVITATION date: 2024-03-01 date: 2025-03-01 date: 2025-03-01 date: 2024-03-18 date: 2024-03-18 name: Kırıkkale University class: OTHER briefSummary: Lung ultrasonography has become frequently used in neonatal intensive care units because it is a diagnostic, useful, harmless, radiation-free, bedside, reproducible and practical method. (1, 2) In our clinic, lung ultrasonography imaging is performed in infants hospitalized with respiratory distress.
AUS imaging has become an objective value by scoring today. Images will be obtained using the linear probe of the device to be used for lung ultrasound and transferred to a cell phone, both lungs will be evaluated as three areas on the right and left (anterior upper, anterior lower and lateral) and scored separately. Anteriorly, the region between the anterior axillary line and the parasternal line is divided into two by the line passing through the nipple. Above is considered as the upper anterior region and below as the lower anterior region. The area in the middle of the anterior and posterior axillary line is evaluated as the lateral region. Each area is scored from 0 to 3 points. If A lines are present, 0 points are given, if there are more than 3 B lines in an area, 1 point is given, if B lines are very dense and there are no A lines, it is considered as white lung and 2 points are given. If there is a consolidation image on AUS, 3 points were given. The maximum total score was 18 (8,9) (Figure 1).
In this study, both AUS imaging and scoring will be performed in the delivery room within the first 30 minutes and AUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients. The hypothesis of this study is that newborns with high AUS scores will have high rates of respiratory morbidities and respiratory support in the neonatal unit. The primary aim of the study was to determine the role and importance of AUS scores measured in the delivery room in predicting respiratory morbidities of infants. The secondary aim was to investigate the value of the course of AUS scores at postnatal 2, 6 and 24 hours in predicting the respiratory prognosis of the newborn infant. conditions: Suspected Damage to Fetus From Other Disease in the Mother, Affecting Management of Mother, With Delivery conditions: Patient Death or Serious Disability Associated With A Haemolytic Reaction Due to the Administration of ABO-Incompatible Blood or Blood Products studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 112 type: ESTIMATED name: doing lung ultrasonography measure: LUS in delivery room measure: LUS in NICU or room sex: ALL minimumAge: 1 Minute maximumAge: 1 Month stdAges: CHILD facility: Kirikkale University city: Kirikkale country: Turkey lat: 39.84528 lon: 33.50639 hasResults: False
nctId: NCT06314776 id: NEURO24 briefTitle: Whole-Body Vibration Therapy in the Gait of Children With Cerebral Palsy overallStatus: RECRUITING date: 2024-03-11 date: 2024-06-01 date: 2024-06-30 date: 2024-03-18 date: 2024-03-18 name: Universidad de Almeria class: OTHER briefSummary: Observation of the effect of vibration therapy on the gait of children with cerebral palsy and the analysis of their functional evolution conditions: Cerebral Palsy conditions: Neurologic Disorder conditions: Gait Disorders in Children conditions: Hemiplegia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 10 type: ESTIMATED name: Usual physiotherapy without Whole-Body Vibration name: Pre-Usual physiotherapy name: Post-Usual physiotherapy measure: Test Time Up and Go measure: Timed 10-Meter Walk Test measure: Gross Motor Function Measure sex: ALL minimumAge: 2 Years maximumAge: 11 Years stdAges: CHILD facility: María del Mar Sánchez-Joya status: RECRUITING city: Almería zip: 04120 country: Spain name: María del Mar Sánchez-Joya, PhD role: CONTACT name: Pilar Pérez Guillén role: SUB_INVESTIGATOR lat: 36.83814 lon: -2.45974 hasResults: False
nctId: NCT06314763 id: ROSIE briefTitle: Rivaroxaban Sotorasib Interaction Study acronym: ROSIE overallStatus: RECRUITING date: 2023-11-09 date: 2024-11 date: 2024-11 date: 2024-03-18 date: 2024-03-18 name: Radboud University Medical Center class: OTHER name: Amgen briefSummary: Venous thromboembolic Events (VTEs) are common in lung cancer patients with an incidence of \>15%, requiring anticoagulant treatment or prophylaxis. Although direct acting oral anticoagulants (DOACs) are the agents of first choice due to ease and patient friendliness, these drugs are often avoided in cancer patients due to suspected pharmacokinetic drug-drug interactions with oncolytic drugs. Sotorasib is the first KRASG12C inhibitor that has been approved by the US \[FDA\] and EU \[EMA\] for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. Sotorasib has a potential to cause CYP3A-mediated drug-drug interactions due to induction of CYP3A and inhibition of P-GP. Rivaroxaban is the most frequently prescribed DOAC in the Netherlands. As rivaroxaban is a substrate for this enzyme and efflux pump, sotorasib may increase or decrease the exposure to rivaroxaban and, thus, impact its benefit-to-risk ratio. To enable safe combination of sotorasib and rivaroxaban, it is pivotal to investigate the magnitude of the pharmacokinetic interaction between these drugs. conditions: Drug Drug Interaction Study studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: An open label single-sequence pharmacokinetic drug-drug interaction study. primaryPurpose: OTHER masking: NONE count: 22 type: ESTIMATED name: Rivaroxaban 20mg name: Sotorasib 960mg measure: The pharmacokinetics (AUC) of single dose rivaroxaban in presence and absence of 960 mg sotorasib at pharmacokinetic steady-state. measure: The pharmacokinetics (Cmax) of single dose rivaroxaban in presence and absence of 960 mg sotorasib at pharmacokinetic steady-state. measure: The pharmacokinetics (AUC) of sotorasib in healthy volunteers. measure: The pharmacokinetics (Cmax) of sotorasib in healthy volunteers. measure: Number of participants with treatment-related adverse events as assessed by CTCAE v6.0 measure: Pharmacokinetic variability in AUC of rivaroxaban. measure: Pharmacokinetic variability in Cmax of rivaroxaban. measure: Pharmacokinetic variability in AUC of sotorasib. measure: Pharmacokinetic variability in Cmax of sotorasib. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Radboud university medical centre status: RECRUITING city: Nijmegen country: Netherlands name: Rob ter Heine role: CONTACT email: R.terHeine@radboudumc.nl name: Rob ter Heine role: PRINCIPAL_INVESTIGATOR lat: 51.8425 lon: 5.85278 hasResults: False
nctId: NCT06314750 id: 2023ZSLYEC-680 briefTitle: Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer overallStatus: ACTIVE_NOT_RECRUITING date: 2010-01-01 date: 2023-09-30 date: 2027-09-30 date: 2024-03-18 date: 2024-03-18 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: Neoadjuvant therapy is the standard diagnosis and treatment strategy for locally advanced rectal cancer defined by MRI in order to achieve tumor regression, thus affecting the selection of surgical strategy and circumferential margin, improving the safety of operation and the prognosis of patients. This study focused on the related clinical factors such as tumor regression before and after neoadjuvant therapy, combined with preoperative high-dimensional features such as radiomics, to predict the related factors of tumor regression of locally advanced rectal cancer, and validate it with multicenter. In order to develop an accurate model that can be applied to the real world and stratify the risk of locally advanced rectal cancer patients before treatment. conditions: Locally Advanced Rectal Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 186 type: ACTUAL measure: OS sex: ALL minimumAge: 20 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06314737 id: 2021ZSLYEC-192 briefTitle: Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer overallStatus: COMPLETED date: 2010-10-02 date: 2018-12-06 date: 2024-01-01 date: 2024-03-18 date: 2024-03-18 name: Sixth Affiliated Hospital, Sun Yat-sen University class: OTHER briefSummary: This study analyzed the efficacy differences between neoadjuvant therapy and direct surgical treatment in patients with locally advanced rectal cancer in the real world. The aim was to evaluate the impact of neoadjuvant therapy on overall survival, disease-free survival, and local recurrence-free survival in patients with locally advanced rectal cancer, explore the population benefiting most from neoadjuvant therapy, and provide evidence-based medicine for the benefits of neoadjuvant therapy in patients with colorectal cancer in the real world. conditions: Locally Advanced Rectal Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3515 type: ACTUAL measure: Overall Survival sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06314724 id: PRO-VZV-4006 briefTitle: Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines overallStatus: ENROLLING_BY_INVITATION date: 2024-03-01 date: 2024-05-15 date: 2024-06-15 date: 2024-03-18 date: 2024-03-18 name: Sinovac (Dalian) Vaccine Technology Co., Ltd. class: INDUSTRY briefSummary: This is a Phase Ⅲ, randomized, double-blind, active-controlled study to assess the immunogenicity and safety of the varicella vaccine,Live (hereinafter referred to as "varicella vaccine")manufactured by Sinovac (Dalian) Vaccine Technology Co., LTD.(hereinafter referred to as "Sinovac"). conditions: Varicella studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 642 type: ESTIMATED name: Varicella Vaccine name: Varivax measure: Seroresponse rate of varicella-zoster virus (VZV) antibody measure: Geometric mean concentrations (GMCs) of VZV antibody measure: GMC of VZV antibody measure: seropositive rate measure: Geometric mean fold rise (GMFR) from before vaccination of VZV antibody measure: Incidence of adverse reactions within 0~42 days after vaccination measure: Incidence of adverse reactions within 0~14 days after vaccination measure: Incidence of serious adverse events (SAE) within 0~42 days after vaccination sex: ALL minimumAge: 12 Months maximumAge: 15 Months stdAges: CHILD facility: San Juan de Dios Educational Foundation, lnc. city: Pasay zip: 1300 country: Philippines lat: 14.53748 lon: 121.00144 facility: Cardinal Santos Medical Center city: San Juan City zip: 1502 country: Philippines lat: 14.6 lon: 121.0333 hasResults: False
nctId: NCT06314711 id: Ex Vivo US for OPC briefTitle: Ex Vivo 3D-ultrasound for Oropharyngeal Cancer overallStatus: COMPLETED date: 2021-10-01 date: 2024-02-01 date: 2024-02-01 date: 2024-03-18 date: 2024-03-18 name: Rigshospitalet, Denmark class: OTHER briefSummary: Patients with biopsy-verified oropharyngeal squamous cell carcinoma or Human Papillomavirus (HPV)-positive unknown primary treated with transoral robotic surgery are included. Immediately post-operatively, freshly resected specimens are examined with ex vivo 3D ultrasound (US).
The primary aim is to explore perioperative ex vivo 3D US for oropharyngeal tumor detection, delineation from normal tissue, tumor size and volume, and margin assessment. conditions: Oropharyngeal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ACTUAL name: Ultrasound measure: Fresh ex vivo US Tumor detection (blinded to histopathology) measure: Margin assessment (blinded to histopathology) measure: Fresh ex vivo US tumor volume (blinded to histopathology) measure: Fresh ex vivo US margin distance (blinded to histopathology) measure: Fresh ex vivo tumor visible on specimen mecrophoto (blinded to histopathology) measure: Fresh ex vivo US tumor volume (unblinded to histopathology) measure: Formalin-fixed ex vivo US tumor volume (unblinded to histopathology) measure: Fresh ex vivo US margin distance (unblinded to histopathology) measure: Formalin-fixed ex vivo US margin distance (unblinded to histopathology) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dept. of Otorhinolaryngology, Head & Neck Surg, Rigshospitalet city: Copenhagen zip: 2100 country: Denmark lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06314698 id: IIT-2024-0011 briefTitle: Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2027-04-30 date: 2024-03-18 date: 2024-03-18 name: RenJi Hospital class: OTHER name: Shanghai JMT-Bio Inc. briefSummary: The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM). conditions: Multiple Myeloma conditions: Bone Diseases studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 478 type: ESTIMATED name: Narlumosbart name: Denosumab measure: Percent change from baseline in urinary N-terminal telopeptide of type 1 collagen corrected for urinary creatinine (uNTx/uCr) at week 13 measure: The proportion of subjects with a change in uNTx/uCr greater than 65% from baseline to week 13 measure: Time to first on-study skeletal related event measure: Percentage of participants with an on-study SRE at different time points measure: Time to first and subsequent on-study SRE measure: Percent changes of serum bone alkaline phosphatase (BALP) and serum C-terminal telopeptide of type 1 collagen (sCTX-I) measure: Overall Survival measure: Incidence and type of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06314685 id: 2020040C-2 briefTitle: Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years overallStatus: ACTIVE_NOT_RECRUITING date: 2021-12-10 date: 2024-08-30 date: 2024-08-30 date: 2024-03-18 date: 2024-04-03 name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd class: INDUSTRY briefSummary: The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old. conditions: Healthy Population studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 2450 type: ACTUAL name: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine name: Group A and C Meningococcal Polysaccharide Vaccine name: Group ACYW135 Meningococcal Polysaccharide Vaccine measure: Antibody positive conversion rate sex: ALL minimumAge: 6 Months maximumAge: 5 Years stdAges: CHILD facility: Hunan Center for Disease Control and Prevention city: Changsha state: Hunan zip: 410005 country: China lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06314672 id: OSU-22318 id: NCI-2023-02217 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: U01CA274999 type: NIH link: https://reporter.nih.gov/quickSearch/U01CA274999 briefTitle: Outreach Project to Connect Underrepresented Populations to Clinical Trials at Ohio State University, CUSP2CT Project Trial overallStatus: RECRUITING date: 2023-08-22 date: 2024-12-31 date: 2025-12-31 date: 2024-03-18 date: 2024-03-18 name: Ohio State University Comprehensive Cancer Center class: OTHER name: National Cancer Institute (NCI) briefSummary: This clinical trial tests the impact of the The Ohio State University Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) project on clinical trial referrals and enrollment in racial/ethnic minorities. Progress in cancer prevention, detection and treatment can only be made by identifying and validating new and improved methods, compounds and modalities in clinical trials. Unfortunately, participation in clinical trials is not equal across all racial and ethnic groups, limiting progress against cancer in all population groups and further widening the disparity gap. To change this picture, concerted effort needs to be directed both at the communities at risk for being left out of trials and the systems that cause the disparities at all levels involved in accrual to clinical trials. The CUSP2CT project may have the potential to increase referral and accrual of racial/ethnic minorities to prevention/control and treatment trials. conditions: Hematopoietic and Lymphoid System Neoplasm conditions: Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 208 type: ESTIMATED name: Accrual name: Discussion name: Educational Activity name: Interview name: Review name: Survey Administration measure: Change in referral to clinical trials (CTs) (short-term outcomes) measure: Change in accrual of minorities to CTs (short-term outcomes) measure: CT accrual and retention due to patient navigation (short-term outcomes) measure: Identification of program gaps in trial accrual (long-term outcomes) measure: Uptake of program in other clinics (long-germ outcomes) measure: Probability of trial enrollment and retention sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center status: RECRUITING city: Columbus state: Ohio zip: 43210 country: United States name: Electra D. Paskett, PhD role: CONTACT phone: 614-293-3917 email: electra.paskett@osumc.edu name: Electra D. Paskett, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06314659 id: 2020020C briefTitle: Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months overallStatus: ACTIVE_NOT_RECRUITING date: 2021-09-17 date: 2024-12-30 date: 2024-12-30 date: 2024-03-18 date: 2024-04-03 name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd class: INDUSTRY briefSummary: The purpose of this study is to evaluate the immunogenicity and safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months old. conditions: Healthy Population studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 630 type: ACTUAL name: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu) name: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax) name: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax) measure: Analysis of antibody positivity conversion rate of serogroup A measure: Analysis of antibody positivity conversion rate of serogroup C sex: ALL minimumAge: 3 Months maximumAge: 5 Months stdAges: CHILD facility: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention city: Nanning state: Guangxi zip: 530028 country: China lat: 22.81667 lon: 108.31667 hasResults: False
nctId: NCT06314646 id: 3747 briefTitle: Transanal Transection and Single-stapled Anastomosis (TTSS) in Rectal Cancer Patients acronym: TTSS-REC overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2027-05-31 date: 2027-12-31 date: 2024-03-18 date: 2024-03-20 name: Istituto Clinico Humanitas class: OTHER briefSummary: The Transanal Transection and Single-Stapled anastomosis (TTSS) technique may be a valid alternative to traditional double-stapled anastomosis for low rectal cancer surgery. This study aims to compare the postoperative and functional outcomes of patients receiving TTSS and traditional double-stapled anastomosis. conditions: Rectal Cancer conditions: Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 472 type: ESTIMATED name: Transanal Transection and Single-Stapled anastomosis (TTSS) name: Double-stapled Total Mesorectal Excision (TME) measure: Rate of anastomotic leak measure: Rate of postoperative complications measure: Postoperative Recovery Profile (PRP) score measure: Proportion of patients fit for stoma closure measure: Healthcare costs measure: Low Anterior Resection Syndrome (LARS) score measure: Low Anterior Resection Syndrome (LARS) score measure: Low Anterior Resection Syndrome (LARS) score measure: Cancer recurrence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False